In a compassionate use study, treatment of adult patients with H3K27M-mutant diffuse midline #glioma with a long peptide #vaccine targeting H3K27M led to peripheral T cell immune responses and encouraging clinical efficacy Niklas Grassl DKFZ The Platten Lab nature.com/articles/s4159…

Huge opportunity to be a leader ⁦Cleveland Clinic⁩ ⁦Cleveland Clinic Abu Dhabi⁩ ⁦Stephen Grobmyer⁩ is looking for a #breastcancer medical oncologist with research and leadership experience!

This week on the Cleveland Clinic Cancer Advances podcast, I talk to Cleveland Clinic MD Michelle Kim Chair Dept Gastroenterology, Hepatology, and Nutrition about management of neuroendocrine tumors my.clevelandclinic.org/podcasts/cance…

Sobering..
nature.com/articles/d4158…

Curative potential of cell therapies with single infusion, low toxicities, vs IO.. labiotech.eu/trends-news/cl…

Beautiful research, strong support for gamma/delta T cells’ role in ICB response. Really nice work! nature.com/articles/s4158…

Here is a very insightful W&A about biotech trends and funding. A similar interview with a focus on cellular therapies would also be quite timely mobihealthnews.com/news/qa-lookin…

Quick reads on interesting developments in the biological sciences. And a happy new year to you all singularityhub.com/2022/12/28/fro…

Base editing: Revolutionary therapy clears girl's incurable cancer - anti-CD7 CAR T cells for T cell leukemias as a bridge to transplant: Powerful! bbc.co.uk/news/health-63…

Off the shelf CAR T cells can be curative. Hopefully more affordable also, which, for many patients (and my Program @CCF) is an important wish & goal fiercebiotech.com/biotech/alloge…

Early-stage investigators proposed innovative high-impact research ideas for the Dr. Monica M. Bertagnolli’s New Innovator Award. See the projects the awardees will pursue: bit.ly/hrhr2022nia #NIHHighRisk

#ICYMI : Comparative Genomics Provides Etiological and Biological Insights into #Melanoma Subtypes, by Newell et al.
bit.ly/3SenG2L
@QIMRBerghofer

This week on Cancer Advances, Dale Shepard MD, PhD is joined by J. Joseph Melenhorst, Director of the Cell Therapy & Immuno-Engineering program & Vice Chair of the Center for Immunotherapy & Precision Immuno-Oncology. Listen as they discuss the future of CAR T-Cell therapy. cle.clinic/3crBVBn

#NewProfilePic